-
1
-
-
0034669484
-
Anastrozole is superior to tamoxifen as first line therapy for advanced breast cancer in postmenopausal women: Results of a North American multicenter randomized trial
-
Arimidex Study Group.
-
Nabholtz JM, Buzdar A, Pollak M et al (2000) Anastrozole is superior to tamoxifen as first line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 18: 3758-3767
-
(2000)
J Clin Oncol
, vol.18
, pp. 37583767
-
-
Nabholtz, J.M.1
Buzdar, A.2
Pollak, M.3
-
2
-
-
0343584508
-
Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: Results of a phase III study of the International Letrozole Breast Cancer Group
-
Mouridsen H, Gershanovich M, Sun Y et al (2001) Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 19: 2596-2606
-
(2001)
J Clin Oncol
, vol.19
, pp. 2596-2606
-
-
Mouridsen, H.1
Gershanovich, M.2
Sun, Y.3
-
3
-
-
0034128928
-
Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: Results of a phase III randomized double blind trial
-
The Exemestane Study Group.
-
Kaufmann M, Bajetta E, Dirix LY et al (2000) Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double blind trial. The Exemestane Study Group. J Clin Oncol 18: 1399-1411
-
(2000)
J Clin Oncol
, vol.18
, pp. 1399-1411
-
-
Kaufmann, M.1
Bajetta, E.2
Dirix, L.Y.3
-
4
-
-
0031054095
-
A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with MA in postmenopausal women with advanced breast carcinoma
-
Budzar AU, Jones SE, Vogel CL et al (1997) A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with MA in postmenopausal women with advanced breast carcinoma. Cancer 79: 730-739
-
(1997)
Cancer
, vol.79
, pp. 730-739
-
-
Budzar, A.U.1
Jones, S.E.2
Vogel, C.L.3
-
5
-
-
0031943424
-
Letrozole, a new aromatase inhibitor for advanced breast cancer double blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate
-
Dombernowsky P, Smith I, Falkson G et al (1998) Letrozole, a new aromatase inhibitor for advanced breast cancer: double blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 16: 453-461
-
(1998)
J Clin Oncol
, vol.16
, pp. 453-461
-
-
Dombernowsky, P.1
Smith, I.2
Falkson, G.3
-
6
-
-
0142181118
-
Anastrozole Alone or in Combination with Tamoxifen versus Tamoxifen Alone for Adjuvant Treatment of Postmenopausal Women with Early-Stage Breast Cancer: Results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) Trial Efficacy and Safety Update Analyses
-
DOI 10.1002/cncr.11745
-
Baum M, Buzdar A, Cuzick J et al (2003) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination.) trial efficacy and safety update analyses. Cancer 98: 1802-1810 (Pubitemid 37310221)
-
(2003)
Cancer
, vol.98
, Issue.9
, pp. 1802-1810
-
-
Baum, M.1
Buzdar, A.2
Cuzick, J.3
Forbes, J.4
Houghton, J.5
Howell, A.6
Sahmoud, T.7
-
7
-
-
29544433211
-
A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer
-
DOI 10.1056/NEJMoa052258
-
Thurlimann B, Keshaviah A, Coates AS et al (2005) A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353: 2747-2757 (Pubitemid 43016814)
-
(2005)
New England Journal of Medicine
, vol.353
, Issue.26
, pp. 2747-2757
-
-
Thurlimann, B.1
Keshaviah, A.2
Coates, A.S.3
Mouridsen, H.4
Mauriac, L.5
Forbes, J.F.6
Paridaens, R.7
Castiglione-Gertsch, M.8
Gelber, R.D.9
Rabaglio, M.10
Smith, I.11
Wardly, A.12
Price, K.N.13
Goldhirsch, A.14
-
8
-
-
10744223655
-
A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer
-
DOI 10.1056/NEJMoa040331
-
Coombes RC, Hall E, Gibson LJ et al (2004) A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350: 1081-1092 (Pubitemid 38298988)
-
(2004)
New England Journal of Medicine
, vol.350
, Issue.11
, pp. 1081-1092
-
-
Coombes, R.C.1
Hall, E.2
Gibson, L.J.3
Paridaens, R.4
Jassem, J.5
Delozier, T.6
Jones, S.E.7
Alvarez, I.8
Bertelli, G.9
Ortmann, O.10
Coates, A.S.11
Bajetta, E.12
Dodwell, D.13
Coleman, R.E.14
Fallowfield, L.J.15
Mickiewicz, E.16
Andersen, J.17
Lonning, P.E.18
Cocconi, G.19
Stewart, A.20
Stuart, N.21
Snowdon, C.F.22
Carpentieri, M.23
Massimini, G.24
Bliss, J.M.25
more..
-
9
-
-
34249936011
-
Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor
-
Goss PE, Ingle JN, Martino S et al (2007) Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor. J Clin Oncol 25: 2006-2011
-
(2007)
J Clin Oncol
, vol.25
, pp. 2006-2011
-
-
Goss, P.E.1
Ingle, J.N.2
Martino, S.3
-
10
-
-
77953022009
-
The role of aromatase inhibitors in adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: Guideline recommendations
-
Accessed 13 Oct 2009
-
Eisen A, Trudeau M, Shelly W et al. (2009) The role of aromatase inhibitors in adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: guideline recommendations. Cancer Care Ont. http://www.cancercare.on.ca/pdf/ pebc1-18f.pdf. Accessed 13 Oct 2009
-
(2009)
Cancer Care Ont.
-
-
Eisen, A.1
Trudeau, M.2
Shelly, W.3
-
11
-
-
42449092417
-
Methodological issues in evaluating cost effectiveness of adjuvant aromatase inhibitors in early breast cancer: A need for improved modeling to aid decision making
-
Annemans L (2008) Methodological issues in evaluating cost effectiveness of adjuvant aromatase inhibitors in early breast cancer: a need for improved modeling to aid decision making. Pharmacoeconomics 26: 409-423
-
(2008)
Pharmacoeconomics
, vol.26
, pp. 409-423
-
-
Annemans, L.1
-
12
-
-
70349914121
-
Using effectiveness and cost-effectiveness to make drug coverage decisions: A comparison of Britain Australia, and Canada
-
Clement FM, Harris A, Li JJ et al (2009) Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada. JAMA 302: 1437-1443
-
(2009)
JAMA
, vol.302
, pp. 1437-1443
-
-
Clement, F.M.1
Harris, A.2
Li, J.J.3
-
13
-
-
0032724035
-
Evaluation of conflict of interest in economic analyses of new drugs used in oncology
-
DOI 10.1001/jama.282.15.1453
-
Friedberg M, Saffran B, Stinson TJ et al (1999) Evaluation of conflict of interest in economic analyses of new drugs used in oncology. JAMA 282: 1453-1457 (Pubitemid 29493799)
-
(1999)
Journal of the American Medical Association
, vol.282
, Issue.15
, pp. 1453-1457
-
-
Friedberg, M.1
Saffran, B.2
Stinson, T.J.3
Nelson, W.4
Bennett, C.L.5
-
14
-
-
0032696499
-
Conflict of interest and cost-effectiveness analysis
-
Krimsky S (1999) Conflict of interest and cost-effectiveness analysis. JAMA 282: 1474-1475
-
(1999)
JAMA
, vol.282
, pp. 1474-1475
-
-
Krimsky, S.1
-
15
-
-
68949135797
-
Comparing the cost of adjuvant anastrozole with the benefits of managing less patients with relapsed breast cancer
-
Thomas RK, Williams M, Glen J et al (2009) Comparing the cost of adjuvant anastrozole with the benefits of managing less patients with relapsed breast cancer. Breast Cancer Res Treat 117(2): 289-295
-
(2009)
Breast Cancer Res Treat
, vol.117
, Issue.2
, pp. 289-295
-
-
Thomas, R.K.1
Williams, M.2
Glen, J.3
-
16
-
-
35748962941
-
Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: A US healthcare system perspective the 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen Alone or in Combination) trial
-
Locker GY, Mansel R, Cella D et al (2007) Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen Alone or in Combination) trial. Breast Cancer Res Treat 106(2): 229-238
-
(2007)
Breast Cancer Res Treat
, vol.106
, Issue.2
, pp. 229-238
-
-
Locker, G.Y.1
Mansel, R.2
Cella, D.3
-
17
-
-
34447326488
-
Cost-effectiveness analysis of anastrozole vs tamoxifen in adjuvant therapy for early stage breast cancer in the United Kingdom: The 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen alone or in combination) trial
-
DOI 10.1038/sj.bjc.6603804, PII 6603804
-
Mansel R, Locker G, Fallowfield L et al (2007) Cost-effectiveness analysis of anastrozole vs tamoxifen in adjuvant therapy for early stage breast cancer in the United Kingdom: the 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen alone or in combination) trial. Br J Cancer 97: 152-161 (Pubitemid 47057463)
-
(2007)
British Journal of Cancer
, vol.97
, Issue.2
, pp. 152-161
-
-
Mansel, R.1
Locker, G.2
Fallowfield, L.3
Benedict, A.4
Jones, D.5
-
18
-
-
33747339240
-
Anastrozole is cost-effective vs tamoxifen as initial adjuvant therapy in early breast cancer: Canadian perspectives on the ATAC completed-treatment analysis
-
Rocchi A, Verma S (2006) Anastrozole is cost-effective vs tamoxifen as initial adjuvant therapy in early breast cancer: Canadian perspectives on the ATAC completed-treatment analysis. Support Care Cancer 14: 917-927
-
(2006)
Support Care Cancer
, vol.14
, pp. 917-927
-
-
Rocchi, A.1
Verma, S.2
-
19
-
-
33947539714
-
Cost-effectiveness of exemestane versus tamoxifen as adjuvant therapy for early-stage breast cancer after 2-3 years treatment with tamoxifen in Sweden
-
DOI 10.1007/s10549-006-9333-6
-
Lundkvist J, Wilking N, Holmberg S et al (2007) Cost-effectiveness of exemestane versus tamoxifen as adjuvant therapy for early-stage breast cancer after 2-3 years treatment with tamoxifen in Sweden. Breast Cancer Res Treat 102: 289-299 (Pubitemid 46474838)
-
(2007)
Breast Cancer Research and Treatment
, vol.102
, Issue.3
, pp. 289-299
-
-
Lundkvist, J.1
Wilking, N.2
Holmberg, S.3
Jonsson, L.4
-
20
-
-
34547102735
-
Cost-effectiveness of switching to exemestane versus continued tamoxifen as adjuvant therapy for postmenopausal women with primary breast cancer
-
DOI 10.1002/cncr.22824
-
Risebrough NA, Verma S, Trudeau M et al (2007) Cost-effectiveness of switching to exemestane versus continued tamoxifen as adjuvant therapy for postmenopausal women with primary breast cancer. Cancer 110: 499-508 (Pubitemid 47106137)
-
(2007)
Cancer
, vol.110
, Issue.3
, pp. 499-508
-
-
Risebrough, N.A.1
Verma, S.2
Trudeau, M.3
Mittmann, N.4
-
21
-
-
34748852542
-
Cost-effectiveness of switching to exemestane after 2 to 3 years of therapy with tamoxifen in postmenopausal women with early-stage breast cancer
-
DOI 10.1111/j.1524-4733.2007.00190.x
-
Thompson D, Taylor DC, Montoya EL et al (2007) Cost-effectiveness of switching to exemestane after 2 to 3 years of therapy with tamoxifen in postmenopausal women with early-stage breast cancer. Value Health 10: 367-376 (Pubitemid 47485660)
-
(2007)
Value in Health
, vol.10
, Issue.5
, pp. 367-376
-
-
Thompson, D.1
Taylor, D.C.A.2
Montoya, E.L.3
Winer, E.P.4
Jones, S.E.5
Weinstein, M.C.6
-
22
-
-
41149179166
-
Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective
-
DOI 10.1007/s10549-007-9607-7
-
Delea TE, El-Ouagari K, Karnon J et al (2008) Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective. Breast Cancer Res Treat 108: 375-387 (Pubitemid 351431071)
-
(2008)
Breast Cancer Research and Treatment
, vol.108
, Issue.3
, pp. 375-387
-
-
Delea, T.E.1
El-Ouagari, K.2
Karnon, J.3
Sofrygin, O.4
-
23
-
-
34347396653
-
Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone receptor-positive postmenopausal women with early-stage breast cancer
-
Delea TE, Karnon J, Sofrygin O et al (2007) Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone receptor-positive postmenopausal women with early-stage breast cancer. Clin Breast Cancer 7: 608-618 (Pubitemid 47025818)
-
(2007)
Clinical Breast Cancer
, vol.7
, Issue.8
, pp. 608-618
-
-
Delea, T.E.1
Karnon, J.2
Sofrygin, O.3
Thomas, S.K.4
Papo, N.L.5
Barghout, V.6
-
24
-
-
34250822270
-
Cost-effectiveness of letrozole in the extended adjuvant treatment of women with early breast cancer
-
DOI 10.1007/s10549-006-9262-4
-
El Ouagari K, Karnon J, Delea T et al (2007) Cost-effectiveness of letrozole in the extended adjuvant treatment of women with early breast cancer. Breast Cancer Res Treat 101: 37-49 (Pubitemid 47555323)
-
(2007)
Breast Cancer Research and Treatment
, vol.101
, Issue.1
, pp. 37-49
-
-
Ouagari, K.E.1
Karnon, J.2
Delea, T.3
Talbot, W.4
Brandman, J.5
-
25
-
-
33644868306
-
Cost effectiveness of extended adjuvant letrozole in postmenopausal women after adjuvant tamoxifen therapy: The UK perspective
-
DOI 10.2165/00019053-200624030-00004
-
Karnon J, Delea T, Johnston SR et al (2006) Cost effectiveness of extended adjuvant letrozole in postmenopausal women after adjuvant tamoxifen therapy: the UK perspective. Pharmacoeconomics 24: 237-250 (Pubitemid 43374376)
-
(2006)
PharmacoEconomics
, vol.24
, Issue.3
, pp. 237-250
-
-
Karnon, J.1
Delea, T.2
Johnston, S.R.3
Smith, R.4
Brandman, J.5
Sung, J.6
Goss, P.E.7
-
26
-
-
33746007227
-
Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer
-
Delea TE, Karnon J, Smith RE et al (2006) Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer. Am J Manag Care 12: 374-386 (Pubitemid 44063449)
-
(2006)
American Journal of Managed Care
, vol.12
, Issue.7
, pp. 374-386
-
-
Delea, T.E.1
Karnon, J.2
Smith, R.E.3
Johnston, S.R.4
Brandman, J.5
Sung, J.C.Y.6
Goss, P.E.7
-
27
-
-
42149091256
-
Cost utility analysis of early adjuvant letrozole or anastrozole versus tamoxifen in postmenopausal women with early invasive breast cancer: The UK perspective
-
Karnon J, Delea T, Barghout V (2008) Cost utility analysis of early adjuvant letrozole or anastrozole versus tamoxifen in postmenopausal women with early invasive breast cancer: the UK perspective. Eur J Health Econ 9: 171-183
-
(2008)
Eur J Health Econ
, vol.9
, pp. 171-183
-
-
Karnon, J.1
Delea, T.2
Barghout, V.3
-
28
-
-
34247847379
-
Cost-utility of adjuvant hormone therapies with aromatase inhibitors in post-menopausal women with breast cancer: Upfront anastrozole, sequential tamoxifen-exemestane and extended tamoxifen-letrozole
-
DOI 10.1016/j.breast.2006.12.002, PII S0960977606002207
-
Skedgel C, Rayson D, Dewar R et al (2007) Cost-utility of adjuvant hormone therapies with aromatase inhibitors in post-menopausal women with breast cancer: upfront anastrozole, sequential tamoxifenexemestane and extended tamoxifen-letrozole. Breast 16: 252-261 (Pubitemid 46796849)
-
(2007)
Breast
, vol.16
, Issue.3
, pp. 252-261
-
-
Skedgel, C.1
Rayson, D.2
Dewar, R.3
Younis, T.4
-
29
-
-
33747475592
-
Pharmacoeconomic analysis of adjuvant therapy with exemestane, anastrozole, letrozole or tamoxifen in postmenopausal women with operable and estrogen receptor-positive breast cancer
-
Gil JM, Rubio-Terrés C, Del Castillo A et al (2006) Pharmacoeconomic analysis of adjuvant therapy with exemestane, anastrozole, letrozole or tamoxifen in postmenopausal women with operable and estrogen receptor-positive breast cancer. Clin Transi Oncol 8: 339-348
-
(2006)
Clin Transi Oncol
, vol.8
, pp. 339-348
-
-
Gil, J.M.1
Rubio-Terrés, C.2
Del Castillo, A.3
-
30
-
-
0345095475
-
Cost-Effectiveness of Anastrozole Versus Tamoxifen as First-Line Therapy for Postmenopausal Women with Advanced Breast Cancer
-
DOI 10.1016/S0149-2918(03)80348-X
-
Simons WR, Jones D, Buzdar A (2003) Cost-effectiveness of anastrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer. Clin Ther 25: 2972-2987 (Pubitemid 37510604)
-
(2003)
Clinical Therapeutics
, vol.25
, Issue.11
, pp. 2972-2987
-
-
Simons, W.R.1
Jones, D.2
Buzdar, A.3
-
31
-
-
0036206298
-
Cost-effectiveness analysis of exemestane compared with megestrol in advanced breast cancer: A model for Europe and Australia
-
Lindgren P, Jönsson B, Redaelli A et al (2002) Cost-effectiveness analysis of exemestane compared with megestrol in advanced breast cancer: a model for Europe and Australia. Pharmacoeconomics 20: 101-108 (Pubitemid 34275759)
-
(2002)
PharmacoEconomics
, vol.20
, Issue.2
, pp. 101-108
-
-
Lindgren, P.1
Jonsson, B.2
Redaelli, A.3
Radice, D.4
-
32
-
-
0035253478
-
Cost-effectiveness analysis of exemestane compared with megestrol in patients with advanced breast carcinoma
-
Hillner BE, Radice D (2001) Cost-effectiveness analysis of exemestane compared with megestrol in patients with advanced breast carcinoma. Cancer 91: 484-489
-
(2001)
Cancer
, vol.91
, pp. 484-489
-
-
Hillner, B.E.1
Radice, D.2
-
33
-
-
0038554367
-
A stochastic economic evaluation of letrozole versus tamoxifen as a first-line hormonal therapy: For advanced breast cancer in postmenopausal patients
-
DOI 10.2165/00019053-200321070-00006
-
Karnon J, Jones T (2003) A stochastic economic evaluation of letrozole versus tamoxifen as a first-line hormonal therapy: for advanced breast cancer in postmenopausal patients. Pharmacoeconomics 21: 513-525 (Pubitemid 36560700)
-
(2003)
PharmacoEconomics
, vol.21
, Issue.7
, pp. 513-525
-
-
Karnon, J.1
Jones, T.2
-
34
-
-
0345688075
-
A trial-based cost-effectiveness analysis of letrozole followed by tamoxifen versus tamoxifen followed by letrozole for postmenopausal advanced breast cancer
-
DOI 10.1093/annonc/mdg447
-
Karnon J, Johnston SR, Jones T et al (2003) A trial-based costeffectiveness analysis of letrozole followed by tamoxifen versus tamoxifen followed by letrozole for postmenopausal advanced breast cancer. Ann Oncol 14: 1629-1633 (Pubitemid 37455811)
-
(2003)
Annals of Oncology
, vol.14
, Issue.11
, pp. 1629-1633
-
-
Karnon, J.1
Johnston, S.R.2
Jones, T.3
Glendenning, A.4
-
35
-
-
0034058430
-
Economic evaluation of letrozole in the treatment of advanced breast cancer in postmenopausal women in Canada
-
DOI 10.1046/j.1524-4733.2000.31004.x
-
Nuijten M, McCormick J, Waibel F et al (2000) Economic evaluation of letrozole in the treatment of advanced breast cancer in postmenopausal women in Canada. Value Health 3: 31-39 (Pubitemid 30232946)
-
(2000)
Value in Health
, vol.3
, Issue.1
, pp. 31-39
-
-
Nuijten, M.1
McCormick, J.2
Waibel, F.3
Parison, D.4
-
36
-
-
0032727949
-
Cost effectiveness of letrozole in the treatment of advanced breast cancer in postmenopausal women in the UK
-
DOI 10.2165/00019053-199916040-00006
-
Nuijten M, Meester L, Waibel F et al (1999) Cost effectiveness of letrozole in the treatment of advanced breast cancer in postmenopausal women in the UK. Pharmacoeconomics 16: 379-397 (Pubitemid 29496048)
-
(1999)
PharmacoEconomics
, vol.16
, Issue.4
, pp. 379-391
-
-
Nuijten, M.1
Meester, L.2
Waibel, F.3
Wait, S.4
-
37
-
-
9644256101
-
Cost utility and budget impact of third-generation aromatase inhibitors for advanced breast cancer: A literature-based model analysis of costs in the Italian national health service
-
DOI 10.1016/j.clinthera.2004.09.014, PII S0149291804803011
-
Marchetti M, Caruggi M, Colombo G (2004) Cost utility and budget impact of third-generation aromatase inhibitors for advanced breast cancer: a literature-based model, analysis of costs in the Italian National Health Service. Clin Ther 26: 1546-1561 (Pubitemid 39572164)
-
(2004)
Clinical Therapeutics
, vol.26
, Issue.9
, pp. 1546-1561
-
-
Marchetti, M.1
Caruggi, M.2
Colombo, G.3
-
38
-
-
0242413719
-
Economic evaluation of antiaromatase agents in the second-line treatment of metastatic breast cancer
-
DOI 10.1007/s00520-003-0502-4
-
Verma S, Rocchi A (2003) Economic evaluation of antiaromatase agents in the second-line treatment of metastatic breast cancer. Support Care Cancer 11: 728-734 (Pubitemid 37432630)
-
(2003)
Supportive Care in Cancer
, vol.11
, Issue.11
, pp. 728-734
-
-
Verma, S.1
Rocchi, A.2
-
39
-
-
0038178935
-
Cost utility analysis of first-line hormonal therapy in advanced breast cancer: Comparison of two aromatase inhibitors to tamoxifen
-
DOI 10.1097/00000421-200306000-00017
-
Dranitsaris G, Verma S, Trudeau M (2003) Cost utility analysis of first-line hormonal therapy in. advanced breast cancer: comparison of two aromatase inhibitors to tamoxifen. Am J Clin Oncol 26: 289-296 (Pubitemid 36712646)
-
(2003)
American Journal of Clinical Oncology: Cancer Clinical Trials
, vol.26
, Issue.3
, pp. 289-296
-
-
Dranitsaris, G.1
Verma, S.2
Trudeau, M.3
-
40
-
-
0033805663
-
Cost-utility analysis of second-line hormonal therapy in advanced breast cancer: A comparison of two aromatase inhibitors to megestrol acetate
-
Dranitsaris G, Leung P, Mather J et al (2000) Cost-utility analysis of second-line hormonal therapy in advanced breast cancer: a comparison of two aromatase inhibitors to megestrol acetate. Anticancer Drugs 11: 591-601
-
(2000)
Anticancer Drugs
, vol.11
, pp. 591-601
-
-
Dranitsaris, G.1
Leung, P.2
Mather, J.3
-
41
-
-
4444291699
-
Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer
-
Hillner BE (2004) Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer, Cancer 101: 1311-1322
-
(2004)
Cancer
, vol.101
, pp. 1311-1322
-
-
Hillner, B.E.1
-
42
-
-
33846475483
-
Cost-utility of adjuvant hormone therapies for breast cancer in post-menopausal women: Sequential tamoxifen-exemestane and upfront anastrozole
-
DOI 10.1007/s10549-006-9299-4
-
Skedgel C, Rayson D, Dewar R et al (2007) Cost-utility of adjuvant hormone therapies for breast cancer in post-menopausal women: sequential tamoxifen-exemestane and upfront anastrozole. Breast Cancer Res Treat 101: 325-333 (Pubitemid 46169887)
-
(2007)
Breast Cancer Research and Treatment
, vol.101
, Issue.3
, pp. 325-333
-
-
Skedgel, C.1
Rayson, D.2
Dewar, R.3
Younis, T.4
-
43
-
-
33847308051
-
Modeling for cost-effective-adjuvant aromatase inhibitor strategies for postmenopausal women with breast cancer
-
DOI 10.1093/annonc/mdl410
-
Younis T, Rayson D, Dewar R et al (2007) Modeling for costeffective-adjuvant aromatase inhibitor strategies for postmenopausal women with breast cancer. Ann Oncol 18: 293-298 (Pubitemid 46323096)
-
(2007)
Annals of Oncology
, vol.18
, Issue.2
, pp. 293-298
-
-
Younis, T.1
Rayson, D.2
Dewar, R.3
Skedgel, C.4
-
44
-
-
31544458993
-
Comparing cost/utility of giving an aromatase inhibitor as monotherapy for 5 years versus sequential administration following 2-3 or 5 years of tamoxifen as adjuvant treatment for postmenopausal breast cancer
-
Lønning PE (2006) Comparing cost/utility of giving an aromatase inhibitor as monotherapy for 5 years versus sequential administration following 2-3 or 5 years of tamoxifen as adjuvant treatment for postmenopausal breast cancer, Ann Oncol 17: 217-225
-
(2006)
Ann Oncol
, vol.17
, pp. 217-225
-
-
Lønning, P.E.1
-
45
-
-
33747614085
-
Pharmacoeconomic aspects of adjuvant anastrozole or tamoxifen in breast cancer: A Slovenian perspective
-
DOI 10.1097/01.cad.0000215057.47695.db, PII 0000181320060700000015
-
Piskur P, Sonc M, Cufer T et al (2006) Pharmacoeconomic aspects of adjuvant anastrozole or tamoxifen in breast cancer: a Slovenian perspective. Anticancer Drugs 17: 719-724 (Pubitemid 44265873)
-
(2006)
Anti-Cancer Drugs
, vol.17
, Issue.6
, pp. 719-724
-
-
Piskur, P.1
Sonc, M.2
Cufer, T.3
Borstnar, S.4
Mrhar, A.5
-
46
-
-
33748760878
-
Cost-effectiveness of anastrozole compared to tamoxifen in hormone receptor-positive early breast cancer. Analysis based on the ATAC trial
-
DOI 10.1111/j.1525-1438.2006.00699.x
-
Moeremans K, Annemans L (2006) Cost-effectiveness of anastrozole compared to tamoxifen in hormone receptor-positive early breast cancer. Analysis based on the ATAC trial. Int J Gynecol Cancer 16: 576-578 (Pubitemid 44410972)
-
(2006)
International Journal of Gynecological Cancer
, vol.16
, Issue.SUPPL. 2
, pp. 576-578
-
-
Moeremans, K.1
Annemans, L.2
|